CLIMB BIO, INC. Proceeds from Issuance of Redeemable Convertible Preferred Stock
CLIMB BIO, INC. (CLYM) reported Proceeds from Issuance of Redeemable Convertible Preferred Stock of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-06.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock · last filed 2023-03-06
- CLIMB BIO, INC. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2022-12-31 was $0.00.
- CLIMB BIO, INC. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2022-09-30 was $0.00.
- CLIMB BIO, INC. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- CLIMB BIO, INC. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- CLIMB BIO, INC. proceeds from issuance of redeemable convertible preferred stock for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- CLIMB BIO, INC. proceeds from issuance of redeemable convertible preferred stock for fiscal 2021 was $93.94M, a 1807.39% increase from fiscal 2020.
- CLIMB BIO, INC. proceeds from issuance of redeemable convertible preferred stock for fiscal 2020 was $4.92M.
| Period end | Proceeds from Issuance of Redeemable Convertible Preferred Stock 3 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 6 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 9 month | Proceeds from Issuance of Redeemable Convertible Preferred Stock 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $0.00 10-K · filed 2023-03-06 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $0.00 derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $59.96M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $59.96M derived: sum of 3 quarters · filed 2023-03-06 | $93.94M 10-K · filed 2023-03-06 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $59.96M derived: sum of 2 quarters · filed 2022-11-14 | $93.94M 10-Q · filed 2022-11-14 | $98.86M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $59.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $93.94M 10-Q · filed 2022-08-15 | $98.86M derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | $33.98M 10-Q · filed 2022-05-16 | $38.90M derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $4.92M 10-K · filed 2022-03-07 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |